{"id":"NCT02607956","sponsor":"Gilead Sciences","briefTitle":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","officialTitle":"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-11","primaryCompletion":"2017-05-12","completion":"2021-07-05","firstPosted":"2015-11-18","resultsPosted":"2018-06-06","lastUpdate":"2022-03-07"},"enrollment":657,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"DTG","otherNames":["Tivicay®"]},{"type":"DRUG","name":"F/TAF","otherNames":["Descovy®"]},{"type":"DRUG","name":"B/F/TAF","otherNames":["GS-9883/F/TAF","Biktarvy®"]},{"type":"DRUG","name":"DTG Placebo","otherNames":[]},{"type":"DRUG","name":"F/TAF Placebo","otherNames":[]},{"type":"DRUG","name":"B/F/TAF Placebo","otherNames":[]}],"arms":[{"label":"B/F/TAF","type":"EXPERIMENTAL"},{"label":"DTG + F/TAF","type":"ACTIVE_COMPARATOR"},{"label":"Open-label Phase B/F/TAF from B/F/TAF","type":"EXPERIMENTAL"},{"label":"Open-label Phase B/F/TAF from DTG + F/TAF","type":"EXPERIMENTAL"}],"summary":"This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm","timeFrame":"Week 48","effectByArm":[{"arm":"B/F/TAF","deltaMin":89.4,"sd":null},{"arm":"DTG + F/TAF","deltaMin":92.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":"0.12"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":125,"countries":["United States","Australia","Belgium","Canada","Dominican Republic","France","Germany","Italy","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["28867499","30932951","31068272","30803969","29956087","31068270","32504574","33880558","39229805","38349226","37200995"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":320},"commonTop":["Nasopharyngitis","Headache","Diarrhoea","Upper respiratory tract infection","Syphilis"]}}